New and potential clinical applications of KRAS as a cancer biomarker (Q38089885)

28 August 2017

New and potential clinical applications of KRAS as a cancer biomarker (English)

1 reference

28 August 2017

0 references

3

Robert Zeillinger

0 references

author name string

Gernot Kriegshäuser

series ordinal

1

1 reference

PubMed ID

23496197

28 August 2017

Veronika Auner

series ordinal

2

1 reference

PubMed ID

23496197

28 August 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

Expert Opinion on Medical Diagnostics

28 August 2017

1 reference

28 August 2017

4

1 reference

28 August 2017

5

1 reference

28 August 2017

383-395

1 reference

EGFR antagonists in cancer treatment

28 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

MicroRNAs targeting mutant K-ras by electrotransfer inhibit human colorectal adenocarcinoma cell growth in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Transcription inhibition of oncogenic KRAS by a mutation-selective peptide nucleic acid conjugated to the PKKKRKV nuclear localization signal peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Sensitive and specific detection of K-ras mutations in colon tumors by short oligonucleotide mass analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Mutation analyses of KRAS exon 1 comparing three different techniques: temporal temperature gradient electrophoresis, constant denaturant capillary electrophoresis and allele specific polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Detection of infrequent and multiple K-ras mutations in human tumors and tumor-adjacent tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Sensitive sequencing method for KRAS mutation detection by Pyrosequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Molecular genetics of lung cancer in people who have never smoked

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Molecular-clinical correlative studies in non-small cell lung cancer: application of a three-tiered approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Topographic analysis of K- ras mutations in histologically normal lung tissues and tumours of lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

KRAS mutations in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

The MAPK signalling pathways and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Recurrent KRAS codon 146 mutations in human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Are RAS mutations predictive markers of resistance to standard chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Impact of EGFR expression on colorectal cancer patient prognosis and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

EGFR FISH in colorectal cancer: what is the current reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Molecular diagnosis of pancreas carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Estimates of the worldwide incidence of 25 major cancers in 1990.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Tamoxifen therapy for breast cancer and endometrial cancer risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.2010.510512

10.1517/17530059.2010.510512

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23496197